Publications:92
Video Visit Available
Accepting New Patients
Mount Sinai DoctorsTreats Adults
Accepting New PatientsJoshua Brody, MD
Internal Medicine, Cancer (Oncology)
No Patient Experience Ratings
Book an Appointment
About Me
Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals including Nature Medicine and Cancer Discovery. Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to use increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation. Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.
Dr. Brody’s research receives funding from numerous grantors, including the National Institutes of Health, the Cancer Research Institute, the Damon Runyon Cancer Research Foundation, and the Lymphoma Research Foundation. He is a member of many professional organizations, including the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology.
Dr. Brody is committed to partnering with his patients to choose the most appropriate treatment approach that offers the best outcomes with excellent quality of life.
Learn more about Dr. Brody's research at The Brody Lab.
Dr. Brody is on Twitter at @joshuabrodyMD
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
About Me
Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals including Nature Medicine and Cancer Discovery. Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to use increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation. Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.
Dr. Brody’s research receives funding from numerous grantors, including the National Institutes of Health, the Cancer Research Institute, the Damon Runyon Cancer Research Foundation, and the Lymphoma Research Foundation. He is a member of many professional organizations, including the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology.
Dr. Brody is committed to partnering with his patients to choose the most appropriate treatment approach that offers the best outcomes with excellent quality of life.
Learn more about Dr. Brody's research at The Brody Lab.
Dr. Brody is on Twitter at @joshuabrodyMD
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
Clinical Focus
- Adult Non-Hodgkin's Lymphoma
- Hodgkin's Disease
- Hodgkin's Lymphoma
- Leukemia
- Lymphoma
- Mantle Cell Lymphoma
- Primary Central Nervous System Lymphoma
Video
Education
BA, Harvard University
MD, State University of NY at Stony Brook School of Medicine
MD, State University of New York Stony Brook School of Medicine
Residency, Internal Medicine
Yale New Haven Hospital
Fellowship, Medical Oncology
Stanford University School of Medicine
Awards
2011
Society for Immunotherapy of Cancer Presidential Award (SITC 26th Annual Meeting)
2011
SCL Award for top abstract submitted to 2011 International Conference on Malignant Lymphoma
Swiss Cancer League
2011
ASCO Merit Award for top 100 abstracts submitted to 2011 Annual Meeting
American Society of Clinical Oncology
2009
‘Outstanding Recent Graduate’
SUNY Stony Brook School of Medicine
2009
Howard Temin Pathway to Independence Award in Cancer Research (K99/R00) – [1 K99 CA140728-01] ”Immunotransplant to Treat Lymphoma” – 09/09 – 08/14
NCI
2008
ASCO Bradley Stuart Beller Foundation Fellowship Merit Award for best abstract submitted to 2008 Annual Meeting
American Society of Clinical Oncology
2008
William Guy Forbeck Scholar Award – invited to present at 2008 Forum
William Guy Forbeck Research Foundation
2008
MCLC featured researcher
Mantle Cell Lymphoma Consortium
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. Zachary S. Morris, Sandra Demaria, Arta M. Monjazeb, Silvia C. Formenti, Ralph R. Weichselbaum, James Welsh, Heiko Enderling, Jonathan D. Schoenfeld, Joshua D. Brody, Heather M. McGee, Michele Mondini, Michael S. Kent, Kristina H. Young, Lorenzo Galluzzi, Sana D. Karam, Willemijn S.M.E. Theelen, Joe Y. Chang, Mai Anh Huynh, Adi Daib, Sean Pitroda, Caroline Chung, Raphael Serre, Clemens Grassberger, Jie Deng, Quaovi H. Sodji, Anthony T. Nguyen, Ravi B. Patel, Simone Krebs, Anusha Kalbasi, Caroline Kerr, Claire Vanpouille-Box, Logan Vick, Todd A. Aguilera, Irene M. Ong, Fernanda Herrera, Hari Menon, Dee Dee Smart, Jalal Ahmed, Robyn D. Gartrell, Christina L. Roland, Fatemeh Fekrmandi, Binita Chakraborty, Eric H. Bent, Tracy J. Berg, Alan Hutson, Samir Khleif, Andrew G. Sikora, Lawrence Fong. The Lancet Oncology
- Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Joshua D. Brody, Judit Jørgensen, David Belada, Régis Costello, Marek Trněný, Umberto Vitolo, David John Lewis, Yasmin H. Karimi, Anna Sureda, Marc André, Björn E. Wahlin, Pieternella J. Lugtenburg, Tony Jiang, Kubra Karagoz, Andrew J. Steele, Aqeel Abbas, Liwei Wang, Malene Risum, Raul Cordoba. Blood
- Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors. Anthony W. Tolcher, Joshua D. Brody, Nishanthan Rajakumaraswamy, Michelle Kuhne, Torsten Trowe, Anees M. Dauki, Shantheri Pai, Ling Han, Kai Wen Lin, Michael Petrarca, Shivaani Kummar. Clinical Cancer Research
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Brody has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Brody has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.